Introductory paragraph
The mechanisms that underpin COVID-19 disease severity, and determine the outcome of infection, are only beginning to be unraveled. The host inflammatory response contributes to lung injury, but circulating mediators levels fall below those in classical ‘cytokine storms’. We analyzed serial plasma samples from 619 patients hospitalized with COVID-19 recruited through the prospective multicenter ISARIC clinical characterization protocol U.K. study and 39 milder community cases not requiring hospitalization. Elevated levels of numerous mediators including angiopoietin-2, CXCL10, and GM-CSF were seen at recruitment in patients who later died. Markers of endothelial injury (angiopoietin-2 and von-Willebrand factor A2) were detected early in some patients, while inflammatory cytokines and markers of lung injury persisted for several weeks in fatal COVID-19 despite decreasing antiviral cytokine levels. Overall, markers of myeloid or endothelial cell activation were associated with severe, progressive, and fatal disease indicating a central role for innate immune activation and vascular inflammation in COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by grants from: the National Institute for Health Research [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059] and by; a National Institute for Health Research (NIHR) Health Protection Research Senior Investigator award to PO; the Imperial Biomedical Research Centre (NIHR Imperial BRC, grant P45058) and the Health Protection Research Unit (HPRU) in Respiratory Infections at Imperial College London and NIHR HPRU in Emerging and Zoonotic Infections at University of Liverpool, both in partnership with Public Health England, [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], Liverpool Experimental Cancer Medicine Centre for providing infrastructure support (Grant Reference: C18616/A25153); a Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund award (to YJC and DH) and the UK Coronavirus Immunology Consortium (UK-CIC). LT is supported by the Wellcome Trust (grant number 205228/Z/16/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Hospitalized patients with PCR-proven or high likelihood of SARS-CoV-2 infection were recruited, including both patients with community- and hospital-acquired COVID-19. This study analyzed plasma from blood samples obtained on the day of enrolment to the study (day 1, Tier 1) and additional serial samples obtained following a sampling schedule (Tier 2) harmonized with international investigators to allow meaningful comparison of results between studies. Healthy controls were recruited prior to December 2019 under approval from the London Fulham Research Ethics Committee (REC) (reference 14/LO/1023) or from healthy donors following informed consent from a sub-collection of the Imperial College Healthcare NHS Trust National Institute for Health Research Imperial Biomedical Research Centre Tissue Bank. Use of the sub-collection was approved by the Tissue Bank Ethics Committee (Approval R12023). Samples from community managed COVID-19 cases were collected through a subproject of Imperial College London Communicable Disease Research Tissue Bank, under approval from the south central Oxford REC (reference 15/SC/0089).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
ISARIC4C data are available for request through an independent data and materials access committee. All other data are available upon reasonable request from the authors.
